(Q37393211)

20 August 2017

1 reference

title

Epidemiology of hormone-related venous thromboembolism (English)

1 reference

20 August 2017

1 reference

Saskia Middeldorp

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

123 Suppl 2

1 reference

20 August 2017

page(s)

S65-9

1 reference

Oral contraceptives and the risk of venous thrombosis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

20 µg versus >20 µg estrogen combined oral contraceptives for contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Incidence and mortality of venous thrombosis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Thrombophilia and venous thromboembolism: implications for testing

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Pros and cons of thrombophilia testing: pros.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Pros and cons of thrombophilia testing: cons

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Is family history sufficient to identify women with risk of venous thromboembolism before commencing the contraceptive pill?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Recurrence of Venous Thromtoembolic Disease and Use of Oral Contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Thrombophilia, clinical factors, and recurrent venous thrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Risk of venous thromboembolism in users of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Hormone replacement therapy (HRT)--risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

The effects of tibolone in older postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970014-3

7 January 2021

10.1016/S0049-3848(09)70014-3

Identifiers

DOI

1 reference

20 August 2017

1 reference